

# Protecting all against tetanus

Guide to sustaining maternal and neonatal tetanus elimination (MNTE) and broadening tetanus protection for all populations



World Health  
Organization



# Protecting all against tetanus

Guide to sustaining maternal and neonatal tetanus elimination (MNTE) and broadening tetanus protection for all populations

Protecting all against tetanus: guide to sustaining maternal and neonatal tetanus elimination (MNTE) and broadening tetanus protection for all populations

ISBN 978-92-4-151561-0

© World Health Organization 2019

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** Protecting all against tetanus: guide to sustaining maternal and neonatal tetanus elimination (MNTE) and broadening tetanus protection for all populations. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in Switzerland

# Contents

|  |           |
|--|-----------|
| Acknowledgments  | v         |
| Abbreviations and acronyms   | vi        |
| About this guide   | vii       |
| <br>   |           |
| <b>Chapter 1:</b>  |           |
| <b>Introduction</b>  | <b>1</b>  |
| Why is there a global goal for maternal and neonatal tetanus elimination (MNTE)?   | 3         |
| How can protection against tetanus and MNTE be sustained?  | 6         |
| <br>   |           |
| <b>Chapter 2:</b>  |           |
| <b>Building routine immunization for long-term protection against tetanus</b>  | <b>9</b>  |
| What is the WHO recommended routine vaccination schedule for TTCV?   | 11        |
| What TTCVs can be used for the childhood vaccination schedule?   | 12        |
| Why use tetanus-diphtheria containing combination vaccines (DT/Td) rather than TT?   | 14        |
| Are TTCVs safe?  | 15        |
| What strategies can be used to achieve high coverage of the primary series of TTCV?  | 16        |
| What strategies and opportunities can be used for TTCV booster doses?  | 19        |
| Is it necessary to introduce all three TTCV booster doses into the immunization schedule together at the same time?                          | 32        |
| What is the catch-up schedule for children >1 year of age or adolescents who missed or did not complete the primary series of TTCV?          | 33        |
| What activities need to be undertaken to ensure successful roll out of a routine childhood 6-dose TTCV schedule?                             | 35        |
| <br>   |           |
| <b>Chapter 3:</b>  |           |
| <b>Antenatal care (ANC) contacts and tetanus vaccination status of pregnant women</b>  | <b>39</b> |
| What is the role of vaccinating pregnant women and how will this change as countries establish the 6-dose routine child/adolescent schedule? | 41        |
| What are current WHO recommendations for antenatal care (ANC) contacts?  | 42        |
| How to screen and vaccinate pregnant women for protection against tetanus?   | 44        |

|   |           |
|---|-----------|
| What records/cards do pregnant women need to keep?  | 47        |
| What does “protection at birth” (PAB) mean and why is it important?                                 | 48        |
| What is routine administrative TTCV2+ coverage monitoring?  | 51        |
| <b>Chapter 4:</b>   |           |
| <b>Ensuring clean birth and umbilical cord care practices</b>                                       | <b>53</b> |
| Why are clean birth and umbilical cord care important for MNTE?                                     | 55        |
| How can clean birth and clean cord care practices be achieved?                                      | 56        |
| What practices ensure a clean birth and cord care?  | 58        |
| What are clean birth kits (CBK) and childbirth checklists?  | 60        |
| <b>Chapter 5:</b>   |           |
| <b>Tetanus surveillance</b>   | <b>65</b> |
| What is tetanus surveillance and why is it necessary?   | 67        |
| What are the WHO recommended standards for tetanus surveillance?                                    | 69        |
| <b>Chapter 6:</b>   |           |
| <b>Monitoring &amp; Evaluation (M&amp;E)</b>  | <b>73</b> |
| What monitoring and evaluation is required for tetanus vaccination?                                 | 75        |
| Programmatic M&E: what monitoring tools need to be in place or revised?                             | 75        |
| How to periodically assess if MNTE status is sustained?   | 77        |
| <b>Annexes</b>  | <b>87</b> |
| Annex 1. What is tetanus?   | 88        |
| Annex 2. Estimating target populations using UN Population Division estimates and projections       | 92        |
| Annex 3. Determining the number of TTCV doses to be administered to a pregnant woman at ANC contact | 94        |
| Annex 4. How to implement the protection at birth (PAB) method in practice?                         | 96        |
| Annex 5. Example of national tally sheet for TTCV2+ (or Td2+) for pregnant women                    | 100       |
| Annex 6. Five moments for hand hygiene  | 101       |
| Annex 7. WHO Recommended Surveillance Standards for Neonatal Tetanus (NT)                           | 102       |
| Annex 8. WHO Recommended Surveillance Standards for Non-NT  | 111       |
| Annex 9. Illustrative example of job aid on screening for vaccine eligibility                       | 120       |
| Annex 10. Serosurveys   | 121       |
| Annex 11. Methodology for a post-validation assessment of MNTE                                      | 132       |

# Acknowledgments

This document was developed by the Expanded Programme on Immunization (EPI), Department of Immunization, Vaccines and Biologicals (IVB) of the World Health Organization (WHO) with extensive review and inputs from numerous colleagues in headquarters and regional offices, individuals and consultants, and partner organizations. Sincere thanks to all those who contributed their experience and knowledge.

This Guide's development and publication was possible thanks to support and contributions from various donors.

## Abbreviations and acronyms

|         |  |
|---------|--|
| AEFI    | Adverse event(s) following immunization          |
| ANC     | Antenatal care                                   |
| CBK     | Clean birth kit                                  |
| CHD     | Child Health Days                                |
| cMYP    | Comprehensive multi-year plan                    |
| DHS     | Demographic and Health Survey                    |
| HBR     | Home-based records                               |
| HMIS    | Health management information system             |
| HPV     | Human papillomavirus                             |
| ICC     | Interagency Coordinating Committee               |
| IEC     | Information, Education and Communication         |
| LQA-CS  | Lot quality assurance – cluster sample           |
| MCHD    | Maternal and Child Health Days                   |
| M&E     | Monitoring and evaluation                        |
| MICS    | Multiple Indicator Cluster Survey                |
| MNTE    | Maternal and neonatal tetanus elimination        |
| NITAG   | National Immunization Technical Advisory Group   |
| Non-NT  | Non-neonatal tetanus                             |
| NT      | Neonatal tetanus                                 |
| PAB     | Protection at birth                              |
| PCV     | Pneumococcal conjugate vaccine                   |
| PIRI    | Periodic intensification of routine immunization |
| RCA     | Root cause analysis                              |
| RED/REC | Reaching Every District/Reach Every Child        |
| SBA     | Skilled birth attendant                          |
| SIA     | Supplementary immunization activity              |

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_24896](https://www.yunbaogao.cn/report/index/report?reportId=5_24896)

